^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements

Published date:
02/08/2022
Excerpt:
We investigated zenocutuzumab (Zeno, MCLA-128), an ADCC-enhanced anti-HER2xHER3 bispecific antibody, in NRG1 fusion-positive...A CD74-NRG1-positive NSCLC patient who had progressed on six prior lines of systemic therapy including afatinib responded rapidly to treatment with a partial response. Targeting HER2 and HER3 simultaneously with Zeno is a novel therapeutic paradigm for patients with NRG1 fusion-positive cancers.
DOI:
https://doi.org/10.1158/2159-8290.CD-21-1119
Evidence Level:
Sensitive: C4 – Case Studies
Title:

PR02 - Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

Published date:
10/27/2019
Excerpt:
A third patient with CD74-NRG1 fusion-positive non-small cell lung cancer (NSCLC) metastatic to the brain was started on MCLA-128. Despite progression on 6 prior lines of systemic therapy including afatinib, he rapidly responded to MCLA-128 with scans showing a partial response (-33%) by RECIST v1.1 at 8 weeks and tumor shrinkage in the brain.
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions

Published date:
03/10/2021
Excerpt:
We tested Zeno in a panel of isogenic and patient-derived cell line...Treatment of mice bearing LUAD-0061AS3, ST3204 and OV-10-0050 PDX tumors (2.5, 8, 25 mg/kg, QW) caused a dose-dependent inhibition of tumor growth, with tumor shrinkage observed at higher doses.